Literature DB >> 1613194

Mediastinitis due to Nocardia asteroides after cardiac transplantation.

F Thaler1, B Gotainer, G Teodori, C Dubois, P Loirat.   

Abstract

Nocardia infection classically occurs in immuno-compromized patients. Only a few cases of mediastinal infection due to this pathogen have been described in the literature. We report a patient who developed mediastinitis due to Nocardia asteroides after cardiac transplantation. The treatment was surgical debridement, dressing, sugaring and antibiotic therapy. The emergence of a severe acute renal failure possibly induced by drug interaction between Cyclosporin, cyclines and aminoglycosides, led us to modify the antimicrobial treatment. The intravenous use of Imipenem 2 g per day and Ciprofloxacin 400 mg per day for four weeks and then oral Ciprofloxacin 1.5 g per day for 1 year, was effective and allowed a good outcome, without any drug interaction with Cyclosporin, adverse effect, graft rejection episode or infection relapse.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1613194     DOI: 10.1007/bf01705048

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  10 in total

1.  Investigation of potential interaction of ciprofloxacin with cyclosporine in bone marrow transplant recipients.

Authors:  H U Krüger; U Schuler; B Proksch; M Göbel; G Ehninger
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine.

Authors:  C K Avent; D Krinsky; J K Kirklin; R C Bourge; W D Figg
Journal:  Am J Med       Date:  1988-09       Impact factor: 4.965

3.  Nephroprotective effect of imipenem/cilastatin in reducing cyclosporine toxicity.

Authors:  B Sido; C Hammer; W Mraz; F Krombach
Journal:  Transplant Proc       Date:  1987-02       Impact factor: 1.066

Review 4.  Immunosuppressive therapy with cyclosporine for cardiac transplantation.

Authors:  B D Kahan
Journal:  Circulation       Date:  1987-01       Impact factor: 29.690

5.  In vitro susceptibilities of Nocardia species to newer antimicrobial agents.

Authors:  P Berkey; D Moore; K Rolston
Journal:  Antimicrob Agents Chemother       Date:  1988-07       Impact factor: 5.191

6.  Use of granulated sugar in treatment of open mediastinitis after cardiac surgery.

Authors:  J L Trouillet; J Chastre; J Y Fagon; J Pierre; Y Domart; C Gibert
Journal:  Lancet       Date:  1985-07-27       Impact factor: 79.321

7.  Nocardial infections in the United States, 1972-1974.

Authors:  B L Beaman; J Burnside; B Edwards; W Causey
Journal:  J Infect Dis       Date:  1976-09       Impact factor: 5.226

8.  Infectious complications in heart transplant recipients receiving cyclosporine and corticosteroids.

Authors:  J M Hofflin; I Potasman; J C Baldwin; P E Oyer; E B Stinson; J S Remington
Journal:  Ann Intern Med       Date:  1987-02       Impact factor: 25.391

9.  Susceptibility of Nocardia asteroides to 46 antibiotics, including 22 beta-lactams.

Authors:  L Gutmann; F W Goldstein; M D Kitzis; B Hautefort; C Darmon; J F Acar
Journal:  Antimicrob Agents Chemother       Date:  1983-02       Impact factor: 5.191

Review 10.  Nocardial infections in the immunocompromised host: A detailed study in a defined population.

Authors:  G L Simpson; E B Stinson; M J Egger; J S Remington
Journal:  Rev Infect Dis       Date:  1981 May-Jun
  10 in total
  3 in total

Review 1.  Infections in solid-organ transplant recipients.

Authors:  R Patel; C V Paya
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

Review 2.  Nocardia species: host-parasite relationships.

Authors:  B L Beaman; L Beaman
Journal:  Clin Microbiol Rev       Date:  1994-04       Impact factor: 26.132

3.  Nocardiosis in a tertiary care hospital in North India and review of patients reported from India.

Authors:  M R Shivaprakash; Pooja Rao; Jharna Mandal; Manisha Biswal; Sunita Gupta; Pallab Ray; Arunaloke Chakrabarti
Journal:  Mycopathologia       Date:  2007-04-24       Impact factor: 3.785

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.